Recursion Pharmaceuticals Inc’s recently made public that its Chief Executive Officer Gibson Christopher unloaded Company’s shares for reported $0.84 million on Mar 27 ’25. In the deal valued at $6.04 per share,138,574 shares were sold. As a result of this transaction, Gibson Christopher now holds 1,117,450 shares worth roughly $6.09 million.
Then, Gibson Christopher bought 138,574 shares, generating $836,987 in total proceeds.
Before that, Gibson Christopher sold 20,000 shares. Recursion Pharmaceuticals Inc shares valued at $131,600 were divested by the Chief Executive Officer at a price of $6.58 per share. As a result of the transaction, Gibson Christopher now holds 1,256,024 shares, worth roughly $6.85 million.
Morgan Stanley initiated its Recursion Pharmaceuticals Inc [RXRX] rating to an Equal-weight in a research note published on May 22, 2023; the price target was $8. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. KeyBanc Capital Markets began covering RXRX with “an Overweight” recommendation on September 16, 2022. BofA Securities revised its rating on April 18, 2022. It rated RXRX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of RXRX
On Tuesday, Recursion Pharmaceuticals Inc [NASDAQ:RXRX] saw its stock jump 1.49% to $5.45. Over the last five days, the stock has gained 24.15%. Recursion Pharmaceuticals Inc shares have fallen nearly -19.38% since the year began. Nevertheless, the stocks have fallen -39.51% over the past one year.
How much short interest is there in Recursion Pharmaceuticals Inc?
A steep rise in short interest was recorded in Recursion Pharmaceuticals Inc stocks on 2025-05-30, growing by 15.92 million shares to a total of 109.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 93.12 million shares. There was a rise of 14.6%, which implies that there is a positive sentiment for the stock.
